Prof. dr hab. Jakub Gołąb is a graduate of medicine at the Faculty of Medicine of the Medical Academy in Warsaw. At the same university he also defended his doctoral thesis. Professor Gołąb has completed his postdoctoral training at Beth Israel Deaconess Medical Center in Boston – a hospital belonging to the Harvard Medical School. In scientific work, he focuses on searching for new and improving existing cancer treatment methods, among others photodynamic therapy, monoclonal antibodies and research on the mechanisms of action of many drugs, including proteasome inhibitors and statins. He is the main coordinator of the multidisciplinary BASTION project (From Basic to Translational Research in Oncology) implemented by ten research groups of the Medical University of Warsaw. Since 2012, he is involved in the operation of the company he founded, specializing in the discovery of new drugs (OncoArendi Therapeutics), which focuses its activities mainly on the discovery and synthesis of compounds directed to inflammatory pathways involved in the pathogenesis of chronic diseases and cancer.

Professor Gołąb is the author of 100 publications (Citation according to ISI:> 4500, Index H: 32).